Taltz Tops Tremfya In Head-To-Head Psoriasis Study On Complete Skin Clearance
Executive Summary
Lilly's IL-17A inhibitor ixekizumab outperformed J&J's IL-23 inhibitor guselkumab on achieving complete skin clearance in moderate-to-severe psoriasis patients at 12 weeks in a head-to-head trial.